| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:3184.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Department of Internal Medicine, University of Texas Medical School at Houston (S.N.H., D.-c.G., R.H., V.T.T., D.M.); the Department of Pediatrics, University of Iowa, Iowa City (M.C.W., A.M.); Human Genome Sequencing Center, Baylor College of Medicine, Houston, Tex (S.E.S.); and the Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, Tex (S.S.S.).
Correspondence to Dianna M. Milewicz, MD, PhD, 6431 Fannin, MSB 1.614, Houston, TX 77030. E-mail Dianna.M.Milewicz{at}uth.tmc.edu
| Abstract |
|---|
|
|
|---|
Methods and Results A 4-generation family with dominant mode of inheritance of TAAD was studied. Affected status was determined by dilation of the ascending aorta, surgical repair of an aneurysm or dissection, or death as the result of aortic dissection. None of the family members evaluated met the diagnostic criteria for Marfan syndrome. After exclusion of known loci for familial TAAD, a genome-wide scan was carried out to map the defective gene causing the disease in the family. A locus was mapped to a 25-cM region on 3p2425 with a maximum multipoint logarithm of the odds score of 4.28.
Conclusions A third locus for nonsyndromic TAAD was mapped to 3p2425 and termed the TAAD2 locus. This locus overlaps a previously mapped second locus for Marfan syndrome, termed the MFS2 locus. Future characterization of the TAAD2 gene will determine if TAAD2 is allelic to MFS2. In addition, identification of the TAAD2 gene will improve the presymptomatic diagnosis of individuals with this life-threatening genetic syndrome and provide information concerning the pathogenesis of the disease.
Key Words: aorta aneurysm genetics mapping
| Introduction |
|---|
|
|
|---|
We identified a large family with multiple members with TAAD but without the ocular or skeletal features of MFS. A genome-wide screen mapped the defective gene causing TAAD in this family to a 25 cM locus on 3p2425, thus establishing this locus as the third locus responsible for autosomal dominant TAAD (TAAD2). Interestingly, this locus overlaps with a controversial locus for a MFS-like connective tissue disorder, the MFS2 locus.610
| Methods |
|---|
|
|
|---|
Genotyping
Fluorescently tagged primers (382 pairs, ABI Prism Linkage mapping sets-MD-10, Applied Biosystems) were used to amplify autosomal polymorphic sequences spaced at 10-cM intervals. Primers to analyze other polymorphic markers were designed according to the Cooperative Human Linkage Center13 and the Genome Database.14 The positions of the markers were based on public genome databases (Ensembl,15 Golden Path,16 and the University of South Hampton-School of Medicine17). The amplified products were analyzed on an ABI Prism 3100 Genetic Analyzer. Genemapper 2 and Genescan software were used for allele assignments (Applied Biosystems). Multiple markers were used to study linkage to known loci of aneurysm formation, FBN1, MFS2, TAA1, and FAA1. Twenty-seven markers spaced on a 32-cM region were used to analyze the putative locus on 12q and 27 markers located on a 30-cM region on 3p were used for fine mapping and defining the critical interval for TAAD2.18
Multiplexed amplification of DNA was done by using three primer sets for genome scan markers with Ampli Taq Gold (Applied Biosystems). The PCR amplifications for fine mapping and sequencing were carried out with the use of HotStart Taq DNA polymerase (Qiagen Inc).
Sequencing
Mutation analysis of candidate gene, FBLN2 (XM_003053), was performed by bidirectional sequence analysis of amplified genomic DNA fragments, using intron-based, exon-specific primers. Total RNA was harvested as previously described from fibroblasts and used for reverse transcription and amplification of the FBLN2 cDNA.4 The amplified DNA fragments were sequenced with the use of a Big-Dye Terminator sequencing kit and analyzed on ABI-3700 sequencer (Applied Biosystems).
Statistical Analysis
Two-point LOD score analysis was carried out for linkage studies at known loci of aneurysm formation and for the genome scan analysis. Multipoint analysis was used for the fine mapping at 12q and 3p loci. Pairwise and multipoint LOD scores were calculated with MLINK and LINKMAP programs of the computer software FASTLINK, version3.P.19,20 Allele frequencies for each marker were obtained by using the founders in the pedigrees and penetrance values were used as reported earlier.4
| Results |
|---|
|
|
|---|
|
Detailed clinical findings for 6 family members are shown in Table 1. Protusio acetabuli and dural ectasia were not noted in any family members. Affected status for genetic linkage studies was determined solely on the presence of an ascending aortic aneurysm or dissection (Table 2). Reduced penetrance and variable age of onset of the aortic disease in the family was indicated by II:5 having mild aortic dilatation, whereas his daughter (III:20) had a normal echocardiogram at age 54 years but her son (IV:18) had an enlarged aortic root. No family member had ectopia lentis. A second individual in the family with Turner syndrome (III:32) had bicuspid aortic valve and coarctation of the aorta but no aortic root dilation and was scored as "unknown" for the linkage analysis. One individual (III:18) was scored as unknown for the linkage analysis but was subsequently found to have a mildly enlarged sinus of Valsalva on echocardiogram (Table 2).
|
|
Mapping of the TAAD2 Locus
The haplotypes and LOD scores for markers at the FBN1, TAAD1, and FAA1 loci excluded the linkage of the TAAD phenotype in TAA035 family to these loci. For MFS2 locus, LOD scores of 1.05 for D3S1266, 0.59 for D3S3659 and -3.5 for D3S1286, were obtained. Haplotype construction at the MFS2 locus indicated that the segregation of the diseased haplotype in two unaffected individuals (III:2 and III:7), excluding linkage of the disease to this locus that was reported to be highly penetrant.7 Therefore, we sought to map another locus for TAAD by using only the TAA035 family to avoid possible problems arising from further genetic heterogeneity for the condition.
A genome-wide screen with 380 polymorphic markers was completed by using the original 12 DNA samples collected (Figure 1, plus symbols). LOD scores were obtained through the use of the MLINK program, assuming an autosomal dominant model with age-dependent penetrance. Eighteen markers demonstrated a suggestive LOD score >0.6 (P=0.05) (data not shown). Further analysis of the positive makers was done with samples from 16 additional family (Figure 1, minus symbols), and markers at two loci on 12q and 3p continued to show evidence of linkage to the phenotype (Table 3). Linkage analysis and haplotype construction with 12q markers in a 23 cM region between markers D12S83 and D12S1030 and samples from 31 TAA035 members excluded the 12q locus.
|
An additional 26 makers located in a 30-cM region on 3p were used to confirm linkage of the phenotype to this locus using DNA from 51 family members (Figure 1). Pairwise analysis showed significant evidence of linkage to multiple markers (Table 4). Multipoint linkage analysis with all markers demonstrated 11 markers to have a positive LOD score above 3.0, with a maximum multipoint LOD score of 4.27 obtained with marker D3S2336 (Figure 2).
|
|
Construction of the 3p haplotype with these 26 markers revealed recombinants between D3S3701 and D3S2301 in individual III:8 at the telomeric end and between D3S1619 and D3S1211 in individual III:5 at the centromeric end, defining a critical interval of 25 cM (Figure 1). Haplotype analysis indicated the segregation of the disease haplotype in 4 adults (III:2, III:20, III:29, and III:31; ages 54, 54, 44, and 38 years, respectively) who did not have any evidence of aortic disease, thus confirming decreased penetrance for the disorder.
Fibulin-2 (FBLN2), an extracellular matrix protein known to interact with fibrillin-1, was located in the critical interval.21 FBLN2 was sequenced by using both genomic DNA and fibroblast cDNA using samples from two affected family members (IV:7, IV:9). Intron-based, exon-specific primers were designed to amplify exons 2 through 16 of FBLN2. Exon 1 was sequenced after amplification from fibroblast RNA by RT-PCR. Three known SNPs in FBLN2 exon 10, G836A, G845A, and G855A, were identified, but no disease-causing alterations were found.
| Discussion |
|---|
|
|
|---|
Interestingly, TAAD2 maps onto MFS2, a previously mapped 9-cM locus between D3S1293 and D3S1283 identified by using a large French family. The phenotype of the affected members in the French family was similar to MFS, with complications in the skeletal and cardiovascular systems but no ocular features. The characterization of the clinical phenotype and the mapping of the locus were controversial and discounted by many investigators.710 Although these 2 loci could result from alterations in different genes, the similarities of the cardiovascular phenotype would suggest that the same gene is responsible for both syndromes. Subsequent to the mapping of the MFS2 locus, there have been no other families identified that have been linked to this locus, either with MFS or familial TAAD.4,5
Two individuals in TAA035 (IV:10 and III:32) had Turner syndrome, which is associated with TAAD, aortic coarctation, and bicuspid aortic valve.22 One individual (IV:10) had an aortic dissection at the age of 14 years, followed by another dissection at 24 years of age. Review of the literature revealed no reports of a woman with Turner syndrome with aortic dissection at such a young age unless coarctation of the aorta was present.2325 Since she has the "affected" 3p haplotype associated with disease in the family, the early onset of her aortic disease may be due to inheriting two genetic conditions that predispose her to this disease. A second woman (III:32) with Turner syndrome in the family had both bicuspid aortic valve and coarctation of the aorta but did not have aortic dilation or dissection at the age of 43 years, consistent with her not inheriting the "affected" 3p haplotype.
One individual (III:18, 35 years of age) who did not inherit the affected haplotype at the TAAD2 locus was subsequently found to have a mildly enlarged sinus of Valsalva on echocardiogram. The nomograms established by Roman et al11 are based on age and body surface area. The age grouping used in this study are birth to 18 years of age, 18 to 40 years of age, and >40 years of age. If individual III:18 were a few years older, his measurements would fall within the normal range for the age group >40 years of age. Therefore, the nomograms used may be less accurate for individuals who fall near the age divisions. Alternatively, this individual may have aortic disease that is etiologically distinct from the aortic disease in other family members. This has been observed previously in a family with an FBN1 mutation who had an individual with aortic dissection who did not carry the mutant allele.26
In summary, we have mapped a second locus for TAAD to 3p2425 and named the locus TAAD2. The genetic heterogeneity of familial TAAD is an obstacle in mapping loci causing the disease and families such as TAA035 become critical in definitively establishing the loci responsible for this condition. We have previously identified a major locus for familial TAAD on 5q (TAAD1), and another minor locus was mapped to 11q (FAA1). Eighteen TAAD families described previously failed to show linkage to 3p2425, indicating that TAAD2 is a minor locus for TAAD.4,5 Since some families are not linked to any of the identified loci for this condition, there is at least one more unmapped locus for familial TAAD. Future characterization of the defective genes at these loci will aid in the clinical treatment of the disease in these families and provide insight into the cause of this condition.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received January 9, 2003; revision received April 10, 2003; accepted April 25, 2003.
| References |
|---|
|
|
|---|
2. Coady MA, Davies RR, Roberts M, et al. Familial patterns of thoracic aortic aneurysms. Arch Surg. 1999; 134: 361367.
3. Milewicz DM, Chen H, Park ES, et al. Reduced penetrance and variable expressivity of familial thoracic aortic aneurysms/dissections. Am J Cardiol. 1998; 82: 474479.[CrossRef][Medline] [Order article via Infotrieve]
4. Guo D, Hasham S, Kuang SQ, et al. Familial thoracic aortic aneurysms and dissections: genetic heterogeneity with a major locus mapping to 5q1314. Circulation. 2001; 103: 24612468.
5. Vaughan CJ, Casey M, He J, et al. Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder. Circulation. 2001; 103: 24692475.
6. Kainulainen K, Steinmann B, Collins F, et al. Marfan syndrome: no evidence for heterogeneity in different populations, and more precise mapping of the gene. Am J Hum Genet. 1991; 49: 662667.[Medline] [Order article via Infotrieve]
7. Boileau C, Jondeau G, Babron MC, et al. Autosomal dominant Marfan-like connective-tissue disorder with aortic dilation and skeletal anomalies not linked to the fibrillin genes. Am J Hum Genet. 1993; 53: 4654.[Medline] [Order article via Infotrieve]
8. Collod G, Babron MC, Jondeau G, et al. A second locus for Marfan syndrome maps to chromosome 3p24.2-p25. Nat Genet. 1994; 8: 264268.[CrossRef][Medline] [Order article via Infotrieve]
9. Gilchrist DM. Marfan syndrome or Marfan-like connective-tissue disorder. Am J Hum Genet. 1994; 54: 553554.[Medline] [Order article via Infotrieve]
10. Dietz H, Francke U, Furthmayr H, et al. The question of heterogeneity in Marfan syndrome. Nat Genet. 1995; 9: 228231.[CrossRef][Medline] [Order article via Infotrieve]
11. Roman MJ, Devereux RB, Kramer-Fox R, et al. Two-dimensional echocardiographic aortic root dimensions in normal children and adults. Am J Cardiol. 1989; 64: 507512.[CrossRef][Medline] [Order article via Infotrieve]
12. De Paepe A, Devereux RB, Dietz HC, et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet. 1996; 62: 417426.[CrossRef][Medline] [Order article via Infotrieve]
13. The Cooperative Human Linkage Center. Available at: http://gai.nci.nih.gov/CHLC./ Accessed May 30, 2003.
14. The Genome Database: An International Collaboration in Support of the Human Genome Project. Available at: http://www.gdb.org./ Accessed May 30, 2003.
15. The Wellcome Trust Sanger Institute. Project Ensembl. Available at: http://www.ensembl.org./ Accessed May 30, 2003.
16. UCSC Genome Bioinformatics. Available at: http://genome.ucsc.edu./ Accessed May 30, 2003.
17. University of South Hampton-School of Medicine. Available at: ftp://cedar.genetics.soton.ac.uk/pub/chrom3/map.html. Accessed May 30, 2003.
18. The University of Texas Health Science Center at Houston. Department of Internal Medicine. Division of Medical Genetics. Available at: http://www.uth.tmc.edu/schools/med/imed/med_gen. Accessed May 30, 2003.
19. Cottingham RW Jr, Idury RM, Schaffer AA. Faster sequential genetic linkage computations. Am J Hum Genet. 1993; 53: 252263.[Medline] [Order article via Infotrieve]
20. Lathrop GM, Lalouel JM, Julier C, et al. Multilocus linkage analysis in humans: detection of linkage and estimation of recombination. Am J Hum Genet. 1985; 37: 482498.[Medline] [Order article via Infotrieve]
21. Reinhardt DP, Sasaki T, Dzamba BJ, et al. Fibrillin-1 and fibulin-2 interact and are colocalized in some tissues. J Biol Chem. 1996; 271: 1948919496.
22. Sybert VP. Cardiovascular malformations and complications in Turner syndrome. Pediatrics. 1998; 101: E11.
23. Akimoto N, Shimizu T, Ishikawa M, et al. The surgical treatment of aortic dissection in a patient with Turners syndrome: report of a case. Surg Today. 1994; 24: 929932.[CrossRef][Medline] [Order article via Infotrieve]
24. Bordeleau L, Cwinn A, Turek M, et al. Aortic dissection and Turners syndrome: case report and review of the literature. J Emerg Med. 1998; 16: 593596.[CrossRef][Medline] [Order article via Infotrieve]
25. Elsheikh M, Casadei B, Conway GS, et al. Hypertension is a major risk factor for aortic root dilatation in women with Turners syndrome. Clin Endocrinol (Oxf). 2001; 54: 6973.[CrossRef][Medline] [Order article via Infotrieve]
26. Francke U, Berg MA, Tynan K, et al. A Gly1127Ser mutation in an EGF-like domain of the fibrillin-1 gene is a risk factor for ascending aortic aneurysm and dissection. Am J Hum Genet. 1995; 56: 12871296.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
V.J. Rodrigues, S. Elsayed, B.L. Loeys, H.C. Dietz, and D.M. Yousem Neuroradiologic Manifestations of Loeys-Dietz Syndrome Type 1 AJNR Am. J. Neuroradiol., September 1, 2009; 30(8): 1614 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Silberbach Bicuspid aortic valve and thoracic aortic aneurysm: toward a unified theory. J. Am. Coll. Cardiol., June 16, 2009; 53(24): 2296 - 2297. [Full Text] [PDF] |
||||
![]() |
A. O. Caglayan and M. Dundar Inherited diseases and syndromes leading to aortic aneurysms and dissections Eur. J. Cardiothorac. Surg., June 1, 2009; 35(6): 931 - 940. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. He, D.-C. Guo, W. Sun, C. L. Papke, S. Duraisamy, A. L. Estrera, H. J. Safi, C. Ahn, L. Maximilian Buja, F. C. Arnett, et al. Characterization of the inflammatory cells in ascending thoracic aortic aneurysms in patients with Marfan syndrome, familial thoracic aortic aneurysms, and sporadic aneurysms. J. Thorac. Cardiovasc. Surg., October 1, 2008; 136(4): 922 - 929. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. D. Pearson, R. Devereux, B. Loeys, C. Maslen, D. Milewicz, R. Pyeritz, F. Ramirez, D. Rifkin, L. Sakai, L. Svensson, et al. Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on Research in Marfan Syndrome and Related Disorders Circulation, August 12, 2008; 118(7): 785 - 791. [Full Text] [PDF] |
||||
![]() |
Z. Touat, L. Lepage, V. Ollivier, P. Nataf, U. Hvass, J. Labreuche, M. Jandrot-Perrus, J.-B. Michel, and G. Jondeau Dilation-Dependent Activation of Platelets and Prothrombin in Human Thoracic Ascending Aortic Aneurysm Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 940 - 946. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Pannu, V. Tran-Fadulu, C. L. Papke, S. Scherer, Y. Liu, C. Presley, D. Guo, A. L. Estrera, H. J. Safi, A. R. Brasier, et al. MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II Hum. Mol. Genet., October 15, 2007; 16(20): 2453 - 2462. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Pape, T. T. Tsai, E. M. Isselbacher, J. K. Oh, P. T. O'Gara, A. Evangelista, R. Fattori, G. Meinhardt, S. Trimarchi, E. Bossone, et al. Aortic Diameter >=5.5 cm Is Not a Good Predictor of Type A Aortic Dissection: Observations From the International Registry of Acute Aortic Dissection (IRAD) Circulation, September 4, 2007; 116(10): 1120 - 1127. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. McKellar, D. J. Tester, M. Yagubyan, R. Majumdar, M. J. Ackerman, and T. M. Sundt III Novel NOTCH1 mutations in patients with bicuspid aortic valve disease and thoracic aortic aneurysms J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 290 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Heegaard, A. Corsi, C. C. Danielsen, K. L. Nielsen, H. L. Jorgensen, M. Riminucci, M. F. Young, and P. Bianco Biglycan Deficiency Causes Spontaneous Aortic Dissection and Rupture in Mice Circulation, May 29, 2007; 115(21): 2731 - 2738. [Abstract] [Full Text] [PDF] |
||||
![]() |
P N Robinson, E Arteaga-Solis, C Baldock, G Collod-Beroud, P Booms, A De Paepe, H C Dietz, G Guo, P A Handford, D P Judge, et al. The molecular genetics of Marfan syndrome and related disorders J. Med. Genet., October 1, 2006; 43(10): 769 - 787. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Loeys, U. Schwarze, T. Holm, B. L. Callewaert, G. H. Thomas, H. Pannu, J. F. De Backer, G. L. Oswald, S. Symoens, S. Manouvrier, et al. Aneurysm Syndromes Caused by Mutations in the TGF-{beta} Receptor N. Engl. J. Med., August 24, 2006; 355(8): 788 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Wiest, S. Hyrenbach, P. Bambul, B. Erker, A. Pezzini, I. Hausser, M.-L. Arnold, J. J. Martin, S. Engelter, P. Lyrer, et al. Genetic Analysis of Familial Connective Tissue Alterations Associated With Cervical Artery Dissections Suggests Locus Heterogeneity Stroke, July 1, 2006; 37(7): 1697 - 1702. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Kirsch, N C. Radu, E. Allaire, and D. Y Loisance Pathobiology of Idiopathic Ascending Aortic Aneurysms Asian Cardiovasc Thorac Ann, June 1, 2006; 14(3): 254 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chen, X. Wang, S. A. Carter, Y. H. Shen, H. R. Bartsch, R. W. Thompson, J. S. Coselli, D. L. Wilcken, X. L. Wang, and S. A. LeMaire A single nucleotide polymorphism in the matrix metalloproteinase 9 gene (-8202A/G) is associated with thoracic aortic aneurysms and thoracic aortic dissection J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 1045 - 1052. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Pannu, V. T. Fadulu, J. Chang, A. Lafont, S. N. Hasham, E. Sparks, P. F. Giampietro, C. Zaleski, A. L. Estrera, H. J. Safi, et al. Mutations in Transforming Growth Factor-{beta} Receptor Type II Cause Familial Thoracic Aortic Aneurysms and Dissections Circulation, July 26, 2005; 112(4): 513 - 520. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Van Kien, F. Mathieu, L. Zhu, A. Lalande, C. Betard, M. Lathrop, F. Brunotte, J.-E. Wolf, and X. Jeunemaitre Mapping of Familial Thoracic Aortic Aneurysm/Dissection With Patent Ductus Arteriosus to 16p12.2-p13.13 Circulation, July 12, 2005; 112(2): 200 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Isselbacher Thoracic and Abdominal Aortic Aneurysms Circulation, February 15, 2005; 111(6): 816 - 828. [Full Text] [PDF] |
||||
![]() |
H. Shibamura, J. M. Olson, C. van Vlijmen-van Keulen, S. G. Buxbaum, D. M. Dudek, G. Tromp, T. Ogata, M. Skunca, N. Sakalihasan, G. Pals, et al. Genome Scan for Familial Abdominal Aortic Aneurysm Using Sex and Family History as Covariates Suggests Genetic Heterogeneity and Identifies Linkage to Chromosome 19q13 Circulation, May 4, 2004; 109(17): 2103 - 2108. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |